



TEXAS STATE BOARD OF PHARMACY

Held via Videoconference

Tuesday, August 3, 2021

MINUTES¹

BOARD BUSINESS MEETING

Tuesday, August 3, 2021

President Julie Spier, R.Ph., called the meeting to order at 9:04 a.m. via videoconference in accordance with the Office of the Texas Governor's suspension of applicable sections of Chapter 551 of the Tex. Gov't Code, effective March 16, 2020, in response to the disaster declaration issued March 13, 2020, for the State of Texas. Other Board Members present via videoconference were Vice President Donnie Lewis, R.Ph.; Treasurer Jenny Downing Yoakum, R.Ph.; Rick Fernandez, R.Ph.; Daniel Guerrero; Lori Henke, Pharm.D.; Bradley A. Miller, Ph.T.R.; Donna Montemayor, R.Ph.; Suzette Tijerina, R.Ph.; and Rick Tisch.

Board Member Chip Thornsburg was not in attendance.

Staff present via videoconference were Allison Vordenbaumen Benz, R.Ph., M.S., Executive Director/Secretary; Kerstin Arnold, General Counsel; Megan Holloway, Acting General Counsel; Timothy L. Tucker, Pharm.D., Executive Director/Secretary Designate; Caroline Hotchkiss, Director of Enforcement; Ann Du, Financial Services Manager; John Griffith, Litigation Counsel; Ann Driscoll, Ph.T.R., Operations Director; Shayda Bakhshi, Outreach Coordinator; and Lily Moreno, Executive Assistant.

A. Announcements

President Spier made general announcements and reviewed the meeting procedures.

Ms. Benz announced that the suspension of the Open Meetings requirements would end effective September 1, 2021, and the November 2, 2021 meeting will be held in person.

¹See agenda and corresponding attachments for supporting materials.

B. Discussion and Approval of Minutes of Previous Meetings (Item B)

Following discussion, the motion was made by Mr. Tisch to approve the minutes of the Board Business Meeting held May 11, 2021; the minutes of the Executive Committee Meetings held May 18 and 20, 2021; the minutes of the Board Business Meeting held May 28, 2021; and the minutes of the Temporary Suspension Hearing held July 22, 2021. The motion was seconded by Mr. Lewis and passed unanimously by roll-call vote.

C. Public Comments

The Board heard public comments from Christopher M. Dembny, R.Ph., Consultant Pharmacist, regarding Amendments Concerning Pharmacies in Freestanding Facilities (Item D.1.3), in support of the proposed amendments to allow a licensed nurse authorized by a pharmacist to perform the loading of an automated medication supply system, while expressing concern regarding the requirement to make a record of withdrawal in the absence of a pharmacist for administration to a patient, and requesting language allowing the medication order in the patient's chart to substitute for the record requirement not be removed as proposed.

The Board also heard public comments from John "Jeff" Carson, R.Ph., Owner/President, Oakdell Compounding Pharmacy, regarding the Discussion Concerning FDA Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (FDA MOU), in support of the recommendations by the Compounding Advisory Group and recommending that the Board delay execution of the FDA MOU until litigation regarding the FDA MOU progresses further. Mr. Carson also spoke regarding Amendments Concerning Pharmacies Compounding Non-Sterile Preparations (Item D.2.3), in support of the proposed amendments.

D. Discussion of and Possible Action Regarding Rules

Ms. Arnold introduced Mr. Griffith to present the rules for adoption and proposal.

Final Adoption of Rules

- Rules Concerning Internship Hours Requirement (§283.4) (Item D.1.1)

Mr. Griffith explained that the Board voted to propose the amendments to §283.4 during its May 11, 2021 meeting. The proposed amendments were published in the June 25, 2021 issue of the *Texas Register*, and no comments were received.

Mr. Griffith directed the Board's attention to the amendments to §283.4 and explained the amendments update the internship hours requirement to reflect that the Board requires the number of intern hours required by the Accreditation Council for Pharmacy Education (ACPE).

Following discussion, and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Fernandez to approve for adoption, by Board Order, the amendments to §283.4, as presented. The motion was seconded by Ms. Henke and passed unanimously by roll-call vote.

- Rules Concerning Fees (§§291.6, 295.5 and 297.4) (Items D.1.2.1, D.1.2.2, and D.1.2.3)

Mr. Griffith explained that the Board voted to propose the amendments to §§291.6, 295.5 and 297.4 during its May 11, 2021 meeting. The proposed amendments were published in the June 25, 2021 issue of the *Texas Register*, and no comments were received.

Mr. Griffith directed the Board's attention to the amendments to §§291.6, 295.5, and 297.4, and explained that based on expected expenses, the amendments to §291.6 increase pharmacy license fees, the amendments to §295.5 increase pharmacist license fees, and the amendments to §297.4 increase pharmacist technician and pharmacy technician trainee registration fees, all effective October 1, 2021. Mr. Griffith presented revised language to §§291.6 and 295.5, adjusting the fees due to the lack of Prescription Monitoring Program integration funding that was not appropriated.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Miller to approve for adoption, by Board Order, the amendments to §§291.6 and 295.5, as revised, and §297.4, as presented. The motion was seconded by Mr. Guerrero and passed unanimously by roll-call vote.

- Rules Concerning Pharmacies in Freestanding Facilities (§§291.76 and 291.151) (Items D.1.3.1 and D.1.3.2)

Mr. Griffith explained that the Board voted to propose the amendments to §§291.76 and 291.151 during its May 11, 2021 meeting. The proposed amendments were published in the June 25, 2021 issue of the *Texas Register*, and written comments were received from the following:

- Lisa Walker, R.Ph., in support of the amendment to remove the language allowing a medication order in a patient's chart to substitute for the record of withdrawal of a drug or device in the absence of a pharmacist to restock a floor stock area, while expressing concern about the amendment to require a record of withdrawal in the absence of a pharmacist for administration to a patient, and suggesting limiting the requirement for controlled substances only;

- Christopher M. Dembny, R.Ph.; Joseph Staller, R.Ph.; Jeff Neale, R.Ph.; Beto Quezada, R.Ph.; Libby Gibbs, R.Ph.; Lisa Walker, R.Ph.; Julie Sifford, R.Ph.; and Jerry Jackson, R.Ph., in support of the amendment to allow a licensed nurse authorized by the pharmacist to perform the loading of an automated medication supply system, while expressing concern regarding the requirement to make a record of withdrawal in the absence of a pharmacist for administration to a patient; and
- Kimberly Persley, M.D., President, Texas Ambulatory Surgery Center Society, in support of the amendment to allow a licensed nurse authorized by the pharmacist to perform the loading of an automated medication supply system, while expressing concern regarding the requirement to make a record of withdrawal in the absence of a pharmacist to restock floor area stock.

Mr. Griffith directed the Board's attention to the amendments to §§291.76 and 291.151 and explained that the amendments allow a licensed nurse who is authorized by the pharmacist to perform the loading of an automated medication supply system; update the time interval in which a pharmacist must verify a drug withdrawal; update the requirements for using a floor stock method of drug distribution; update records requirements; and correct grammatical errors. He explained the proposed amendments to §291.151 also update references to DEA 222 form requirements to be consistent with federal regulations.

Following discussion, the motion was made by Mr. Guerrero to approve for adoption amendments to §§291.76 and 291.151, revised to maintain the language allowing a medication order in a patient's chart to substitute for the record of withdrawal. The motion was seconded by Mr. Lewis and passed unanimously by roll-call vote.

- Rules Concerning Automated Dispensing and Delivery Systems (§291.121) (Item D.1.4)

Mr. Griffith explained that the Board voted to propose the amendments to §291.121 during its May 11, 2021 meeting. The proposed amendments were published in the June 25, 2021 issue of the *Texas Register*, and no comments were received.

Mr. Griffith directed the Board's attention to the amendments to §291.121 and explained that the amendments authorize a Class A or Class C pharmacy to provide remote pharmacy services using an automated dispensing and delivery system and correct grammatical errors. Mr. Griffith also explained that these rules originated with a pilot project and had been allowed over the last year through the Office of the Texas Governor's suspensions of certain requirements in response to the COVID-19 disaster declaration.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Lewis to approve for adoption, by Board Order, the amendments to §291.121, as presented. The motion was seconded by Mr. Tisch and passed unanimously by roll-call vote.

Proposal of Rules

- Rules Concerning Licenses and Registrations for Military Service Members, Military Veterans, and Military Spouses (§§283.12 and 297.10) (Items D.2.1.1 and D.2.1.2)

Mr. Griffith directed the Board's attention to suggested amendments to rule language concerning licenses and registrations for military service members, military veterans, and military spouses. He explained the proposed amendments to §§283.12 and 297.1 specify that a copy of a permanent change of station order may be used as proof of a military spouse's residency and add a new service branch to the definition of armed forces of the United States, in accordance with House Bill 139 of the 87th Legislative Session.

Following discussion, the motion was made by Mr. Miller to approve for proposal amendments to §§283.12 and 297.10, as presented. The motion was seconded by Mr. Guerrero and passed unanimously by roll-call vote.

- Rules Concerning Emergency Refill of Insulin and Insulin-Related Equipment or Supplies (§291.34) (Item D.2.2)

Mr. Griffith directed the Board's attention to suggested amendments to rule language concerning emergency refill of insulin and insulin-related equipment or supplies. He explained the proposed amendments to §291.34 clarify that a pharmacist may provide an emergency refill of insulin or insulin-related equipment or supplies under certain conditions, in accordance with House Bill 1935 of the 87th Legislative Session.

Ms. Montemayor asked if the language could be modified to allow the supply for insulin to not exceed a 30-day supply or the smallest supply available. Ms. Holloway advised that the suggested rule language was pulled directly from the bill and could not be modified to be less restrictive.

Following discussion, the motion was made by Mr. Lewis to approve for proposal amendments to §291.34, as presented. The motion was seconded by Mr. Fernandez and passed unanimously by roll-call vote.

President Spier recessed the meeting at 9:59 a.m.
President Spier reconvened the meeting at 10:19 a.m.

- Rules Concerning Pharmacies Compounding Non-Sterile Preparations (§§291.36, 291.77, 291.106 and 291.131) (Items D.2.3.1, D.2.3.2, D.2.3.3, and D.2.3.4)

Mr. Griffith directed the Board's attention to suggested amendments to rule language concerning pharmacies compounding non-sterile preparations. He explained that the proposed amendments to §291.36 create the designation of Class A-N for community pharmacies engaged in the compounding of certain non-sterile preparations and Class A-SN for community pharmacies engaged in the compounding of both sterile and certain non-sterile preparations; the proposed amendments to §291.77 create the designation of Class C-N for institutional or ASC pharmacies engaged in the compounding of certain non-sterile preparations and Class C-SN for institutional or ASC pharmacies engaged in the compounding of both sterile preparations and certain non-sterile preparations; the proposed amendments to §291.106 create the designation of Class E-N for non-resident pharmacies engaged in the compounding of certain non-sterile preparations and Class E-SN for non-resident pharmacies engaged in the compounding of both sterile preparations and certain non-sterile preparations; and the amendments to §291.131 add definitions of "cleaning" and "sanitizing," update requirements for all personnel engaged in non-sterile compounding, add additional requirements for personnel engaged in certain types of non-sterile compounding, and update environmental and equipment requirements for non-sterile compounding. Mr. Griffith explained that these proposed amendments were suggested on the recommendation of the Compounding Advisory Group.

Following discussion, the motion was made by Mr. Guerrero to approve for proposal amendments to §§291.36, 291.77, 291.106 and 291.131, as presented. The motion was seconded by Mr. Lewis and passed 7-2-0 by roll-call vote, with Mr. Fernandez and Ms. Montemayor opposed.

F. Discussion of and Possible Action Concerning the Following Reports and Discussions

- Professional Recovery Network
 - Ms. Hotchkiss discussed performance measures regarding the number of individuals participating in the peer assistance program for the third quarter of FY2021 (March 1, 2021 – May 31, 2021). (Item F.2.1)
 - Ms. Hotchkiss recognized PRN Program Director Raquel Leal, LPC. Ms. Leal directed the Board's attention to the PRN expense report for the third quarter of FY2021 (March 1, 2021 – May 31, 2021) and reviewed PRN activities for the Board. (Item F.2.2)

- Review and Approval of TSBP FY2021 Annual Internal Audit Report (Item F.3)

President Spier recognized Kimberly Lopez-Gonzales and Chika Cherry, with Garza/Gonzalez & Associates. Ms. Lopez-Gonzales explained the observations and findings of the FY2021 Annual Internal Audit Report along with the recommendations. Ms. Lopez-Gonzales also reviewed the observations and findings of the follow-up of prior year audits.

Following discussion, the motion was made by Mr. Guerrero to approve the FY2021 Annual Internal Audit Report, as presented. The motion was seconded by Mr. Lewis and passed unanimously by roll-call vote.

E. Discussion of and Possible Action Concerning Reports of Committees/ Task Forces

- Report on Compounding Advisory Group (Item E.1)

Ms. Benz directed the Board's attention to the drafted minutes from the Compounding Advisory Group meeting that was held on June 24, 2021, via videoconference.

- Group Recommendations Concerning FDA Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (Item E.1.1)

Ms. Holloway explained that at the February Board meeting, the Board requested the Compounding Advisory Group to hear comments from stakeholders regarding the FDA Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (FDA MOU). Ms. Holloway reported that the Compounding Advisory Group recommended that the FDA MOU not be executed by the Board, that the concerns identified by Board staff be communicated to FDA, and that the Board request a two-year extension for enforcement of the FDA MOU.

F. Discussion of and Possible Action Concerning the Following Reports and Discussions, continued

- Discussion Concerning FDA Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (Item F.11)

Ms. Holloway explained that beginning October 25, 2021, FDA planned to start enforcing a 5% limit on compounded drugs distributed outside of the state by a pharmacy located in a state that has not signed the FDA MOU, and that patient specific prescriptions were included in the FDA's definition of distribution. Ms. Holloway directed the Board's attention to the TSBP

Summary of Issues Relating to the FDA MOU and reviewed those for the Board.

Following discussion, a motion was made by Ms. Yoakum to postpone a decision regarding executing the FDA MOU, to send information to the FDA concerning the issues identified by Board staff, and to request a two-year extension for enforcement of the FDA MOU. The motion was seconded by Mr. Lewis and passed unanimously by roll-call vote.

E. Discussion of and Possible Action Concerning Reports of Committees/ Task Forces, continued

- Report on Compounding Advisory Group (Item E.1), continued
 - Group Recommendations Concerning Virtual Training for Individuals Performing Sterile Compounding (Item E.1.2)

Ms. Holloway explained that at the February Board meeting the Board had requested the Compounding Advisory Group review virtual training for individuals performing sterile compounding and provide recommendations, after hearing concerns regarding this matter from a member of the public. Ms. Holloway reviewed the recommendations from the Compounding Advisory Group for the Board.

Following discussion, no action was taken regarding virtual training for individuals performing sterile compounding.

- Report on Prescription Monitoring Program (PMP) Advisory Committee (Item E.2)

Ms. Benz reported that the PMP Advisory Committee meeting was held via videoconference on June 16, 2021, and directed the Board's attention to the drafted minutes for this meeting. She explained that in response to the Board not receiving funding for the PMP integration and NarxCare, the committee discussed alternative methods for funding, however, there were not currently any viable options. Ms. Benz stated that the PMP Advisory Committee will meet again on October 13, 2021.

President Spier recessed the meeting at 12:10 p.m.
President Spier reconvened the meeting at 12:55 p.m.

F. Discussion of and Possible Action Concerning the Following Reports and Discussions, continued

- Financial Report

- Review of FY2021 Third Quarter Expenditures (Item F.1.1)

Ms. Du reviewed the expenditures for the third quarter of FY2021 (March 1, 2021 – May 31, 2021) for the Board.

- Review of Board Member Travel Budget (Item F.1.2)

Ms. Du reviewed the third quarter FY2021 Board Member Travel Budget (March 1, 2021 – May 31, 2021) and explained that the travel budget remains unspent due to COVID-19.

- Consideration of Material Changes to Contracts for Goods and Services Awarded Under Chapter 2155 of Texas Government Code (Item F.1.3)

Ms. Du reviewed the list of updated contracts for goods and services for the third quarter of FY2021 (March 1, 2021 – May 31, 2021) for the Board. She explained that the updates are extensions to the terms of existing contracts and there are no material changes to the contracts.

- Review and Approval of FY2022 Operating Budget (Item F.1.4)

Ms. Du directed the Board's attention to the proposed operating budget for FY2022.

Following review, a motion was made by Mr. Lewis to approve the FY2022 Operating Budget, as presented. The motion was seconded by Mr. Guerrero and passed unanimously by roll-call vote.

- Review and Approval of TSBP FY2022 Goals and Objectives (Item F.4)

Ms. Benz directed the Board's attention to the Goals and Objectives for FY2022.

Following review, the motion was made by Mr. Miller to approve the TSBP FY2022 Goals and Objectives. The motion was seconded by Mr. Tisch and passed unanimously by roll-call vote.

- Review and Approval of Accreditation Council for Pharmacy Education (ACPE) Accredited Professional Programs of Colleges and Schools of Pharmacy (Item F.5)

Ms. Benz directed the Board's attention to a list of ACPE accredited programs of colleges and schools of pharmacy.

Following review, a motion was made by Mr. Lewis to approve the list of ACPE accredited programs of colleges and schools of pharmacy, as presented. The motion was seconded by Mr. Miller and passed unanimously by roll-call vote.

- Review of Timeline for TSBP FY2023-2027 Strategic Plan (Item F.6)

Ms. Benz reviewed the timeline for the TSBP FY2023-2027 Strategic Plan for the Board.

- Review of FY2022 Calendar of Events (Item F.7)

Ms. Benz reviewed the FY2022 Calendar of Events (September 1, 2021 - August 31, 2022) for the Board.

- Report on the Prescription Monitoring Program (Item F.8)

Ms. Benz reviewed the Prescription Monitoring Program data for the third quarter of FY2021 (March 1, 2021 – May 31, 2021).

- Report on Appeals from State Office of Administrative Hearing Cases and Other Court Actions (Item F.9)

Ms. Holloway provided an update concerning the appeal status of the *Garrett* lawsuit that was filed in district court in Travis County and sought to invalidate the restriction that licensed Texas physicians cannot dispense prescriptions to patients at their offices without a pharmacy license. Ms. Holloway advised that for the appeal process the Board is being represented by an attorney from the Office of the Solicitor General. She explained that the opening brief had been filed and the plaintiff's reply was due August 3, 2021, and that after the reply is filed, the court could set the case for oral argument or decide the case without oral argument.

Ms. Holloway provided an update concerning an appeal filed by CVS/pharmacy #7816 (Texas Pharmacy License #24526), following the entry of the Board order at the February Board meeting that was entered after a hearing held by the State Office of Administrative Hearings. She explained that the Board is being represented by an attorney from the Office of the Attorney General in the appeal process.

Ms. Holloway reported on the *Whole Women's Health* lawsuit, concerning Senate Bill 8 of the 87th Legislative Session, also called the "fetal heartbeat" bill. She explained that the plaintiffs are suing the Executive Directors of the Texas Medical Board, the Texas Board of Nursing, and the Texas State Board of Pharmacy; the Executive Commissioner of the Texas Public Health and Human Services Commission; and the Texas Attorney General. Ms. Holloway explained that the case is pending in federal district court and an attorney from the Office of the Attorney General has been appointed to handle the case for the Board and the other defendants.

Ms. Holloway reported on a lawsuit filed by Lightcare Rx, LLC (Texas Pharmacy License #32609) in federal district court. She provided background explaining that Board staff filed and served notice of a hearing at the State Office of Administrative Hearings, following an informal conference held in March 2021 regarding the alleged failure of the pharmacy to operate. She explained that the lawsuit alleges that the Board's failure to operate rule is unconstitutional and discriminates against pharmacies in HEAT zones, i.e., geographic areas designated by Centers for Medicare and Medicaid Services (CMS) with purportedly high rates of healthcare fraud. Ms. Holloway reported that Board staff has requested representation from the Office of the Attorney General.

- Update on Legislation Passed During the 87th Texas Legislative Session that has an Impact on TSBP and/or the Practice of Pharmacy (Item F.10)

Ms. Benz directed the Board's attention to a chart showing legislation Board staff is tracking that has an impact on TSBP and/or the practice of pharmacy, which includes three bills that require action by the Board, two of which were heard earlier with the proposed rules. She explained that the third bill requiring action by the Board requires collaboration with the Texas State Board of Dental Examiners, and more information will be available at the next Board meeting in November 2021.

- Discussion Concerning Hormone Pellet Compounding Process and Terminal Sterilization Process by a Third-Party Provider (Item F.12)

Ms. Benz directed the Board's attention to a letter received from College Pharmacy of Colorado Springs, Colorado, regarding a hormone pellet compounding process and explained that the pharmacy is requesting the process to be considered non-sterile and not subject to the sterile compounding requirements.

Following discussion, the Board members determined to direct the Compounding Advisory Group to review the process and provide recommendations.

G. Consideration of and Possible Action Concerning Enforcement Reports

- Report on Complaints Closed and Dismissed During the Previous Quarter (Item G.1)

Ms. Hotchkiss reported on complaints dismissed and closed during the third quarter of FY2021 (March 1, 2021 – May 31, 2021). The report also included a comparison of complaints closed with disciplinary orders to those closed without disciplinary orders and a comparison of the third quarter of FY2021 to the quarterly averages for FY2020, as well as percentage change from FY2020 to FY2021.

- Report on Status of Active/Pending Complaints (Item G.2)

Ms. Hotchkiss reviewed the *Report on Status of Active/Pending Complaints* for the Board.

H. Disciplinary Orders

- Report on Agreed Board Orders Entered by Executive Director (Item H.1)
 - The Board reviewed 6 Agreed Board Orders concerning pharmacy technicians and pharmacy technician trainees that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from June 24, 2021, through July 30, 2021.
 - The Board reviewed 2 Agreed Board Orders concerning pharmacies and pharmacists that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from July 13, 2021, through July 21, 2021.
 - The Board reviewed 2 Confidential Agreed Board Orders concerning pharmacists that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, on August 2, 2021.
- Discussion of and Action on Proposed Agreed Board Orders, Proposed Default Board Orders, and Proposed Remedial Plans (Items H.2 and H.3)

The Board reviewed the alleged violations, as well as the recommended sanctions for each of the following:

- 25 proposed Agreed Board Orders concerning pharmacy technicians and pharmacy technician trainees who appeared for an Informal Conference;

- 6 proposed Default Board Orders concerning pharmacy technicians and pharmacy technician trainees who did not appear for an Informal Conference;
- 16 proposed Agreed Board Orders concerning pharmacies and pharmacists (Alternative Resolutions);
- 1 Temporary Suspension Order concerning a pharmacist (Following Temporary Suspension Hearing);
- 10 proposed Agreed Board Orders concerning pharmacies, pharmacists, and interns who appeared for an Informal Conference;
- 1 proposed Default Board Order concerning a pharmacist who did not appear for an Informal Conference;
- 1 proposed Confidential Agreed Board Order concerning a pharmacist (Alternative Resolution);
- 9 proposed Confidential Agreed Board Orders concerning pharmacists and interns who appeared for an Informal Conference;
- 8 proposed Remedial Plans concerning pharmacists (Alternative Resolutions); and
- 3 proposed Remedial Plans concerning pharmacies and pharmacists following an Informal Conference.

The motion was made by Mr. Lewis to approve the proposed Disciplinary Orders and Remedial Plans, as presented. The motion was seconded by Mr. Miller. A roll-call vote was taken, and the motion passed as follows:

No.	Name	T, I, R, or P*	ABO, DBO, TSO, or RP**	Order # or Plan #	Board Vote (Yes-No- Recuse)	Recused Board Members
1	Cedric Martin Washington	T	ABO	2021-02376	8-0-1	Henke
2	Aaron Dowdell	T	ABO	2019-04547	7-0-2	Henke, Miller
3	Kandi Espree	T	ABO	2020-00264	7-0-2	Henke, Miller
4	Melony Marie Lucio	T	ABO	2021-01902	7-0-2	Henke, Miller
5	Rodney Scott Pena	T	ABO	2021-03262	7-0-2	Henke, Miller
6	Israel Joel Ramirez	T	ABO	2021-00044	7-0-2	Henke, Miller
7	Kimberly Michelle Russell	T	ABO	2021-01718	7-0-2	Henke, Miller
8	Kenia Yamilet Serna	T	ABO	2020-00607	7-0-2	Henke, Miller
9	Meisha Anise Stone	T	ABO	2021-01939	7-0-2	Henke, Miller
10	Collette Mia Alejandro	T	ABO	2021-00428	7-0-2	Lewis, Tijerina
11	Andrew Castaneda	T	ABO	2021-01493	7-0-2	Lewis, Tijerina

*Technician or Technician Trainee (T), Intern (I), Pharmacist (R), and Pharmacy (P)

**Agreed Board Order (ABO), Default Board Order (DBO), Temporary Suspension Order (TSO), and Remedial Plan (RP)

TSBP Board Business Meeting

Minutes/August 3, 2021

Page 14

No.	Name	T, I, R, or P*	ABO, DBO, TSO, or RP**	Order # or Plan #	Board Vote (Yes-No-Recuse)	Recused Board Members
12	Marlyn Chapa	T	ABO	2020-01825	7-0-2	Lewis, Tijerina
13	Kimberly Louise Doubrava	T	ABO	2020-04100	7-0-2	Lewis, Tijerina
14	Leah Ashley Goch	T	ABO	2020-03967	7-0-2	Lewis, Tijerina
15	Janay Green	T	ABO	2020-01520	7-0-2	Lewis, Tijerina
16	Melissa V. Johnson	T	ABO	2021-02318	7-0-2	Lewis, Tijerina
17	Jonah Matthew Parton	T	ABO	2021-03086	7-0-2	Lewis, Tijerina
18	Jasmine Bryant	T	ABO	2021-01778	7-0-2	Lewis, Tisch
19	Justin David Cartwright	T	ABO	2021-01498	7-0-2	Lewis, Tisch
20	Jordan De La Torre	T	ABO	2019-05564	7-0-2	Lewis, Tisch
21	Kevin Ray Hypolite	T	ABO	2021-02129	7-0-2	Lewis, Tisch
22	Jessica Moreno	T	ABO	2021-02568	7-0-2	Lewis, Tisch
23	Deondra Watson	T	ABO	2021-01391	7-0-2	Lewis, Tisch
24	Nadine Nicola Whitehead	T	ABO	2020-04056	7-0-2	Lewis, Tisch
25	Gina Witherspoon	T	ABO	2021-00664	7-0-2	Lewis, Tisch
26	Nicholas Ford	T	DBO	2020-00622	7-0-2	Henke, Miller
27	Jacob Vanmeter	T	DBO	2019-06153	7-0-2	Henke, Miller
28	Jay Nicolas Eisenberg	T	DBO	2020-00691	7-0-2	Lewis, Tisch
29	Kyran Deon Finnie	T	DBO	2021-00092	7-0-2	Lewis, Tisch
30	Clarissa Gutierrez	T	DBO	2021-00738	7-0-2	Lewis, Tisch
31	Lillian Claire Neumeier	T	DBO	2020-01504	7-0-2	Lewis, Tisch
32	B & J Pharmacy, Inc.	P	ABO	2020-03120	9-0-0	-
33	Michael Lacey	R	ABO	2021-01250	9-0-0	-
34	Baylor Scott & White Pharmacy #110	P	ABO	2020-03112	9-0-0	-
35	Arthur Nathaniel Billings	R	ABO	2020-03632	9-0-0	-
36	City Drug Store	P	ABO	2020-03558	9-0-0	-
37	Costco Pharmacy #1322	P	ABO	2020-03993	9-0-0	-
38	CVS/pharmacy #3701	P	ABO	2020-02239	8-0-1	Tijerina
39	CVS/pharmacy #6856	P	ABO	2019-02870	8-0-1	Tijerina
40	CVS/pharmacy #8990	P	ABO	2020-03111	8-0-1	Tijerina
41	Amber Michelle Casanova	R	ABO	2021-00819	8-0-1	Tijerina
42	Keith Marcell Hudson	R	ABO	2021-03238	9-0-0	-
43	Kroger Specialty Infusion CA	P	ABO	2020-02929	9-0-0	-
44	Walgreens #7775	P	ABO	2020-01115	8-0-1	Fernandez
45	Walgreens #15931	P	ABO	2020-05159	8-0-1	Fernandez
46	Walmart Pharmacy #10-220	P	ABO	2021-00655	9-0-0	-
47	Jason Anthony Zucha	R	ABO	2021-01220	9-0-0	-
48	Venkata Ramanarao Yarlagadda	R	TSO	2021-04704	7-0-2	Fernandez, Lewis
49	Innocent Akani	R	ABO	2021-03603	7-0-2	Lewis, Tisch
50	John Bosnjak	R	ABO	2021-02740	7-0-2	Lewis, Tijerina
51	CVS/pharmacy #2701	P	ABO	2020-04354	6-0-3	Lewis, Tisch, Tijerina
52	Sylvia Dikas	R	ABO	2021-02772	7-0-2	Lewis, Tisch

*Technician or Technician Trainee (T), Intern (I), Pharmacist (R), and Pharmacy (P)

**Agreed Board Order (ABO), Default Board Order (DBO), Temporary Suspension Order (TSO), and Remedial Plan (RP)

No.	Name	T, I, R, or P*	ABO, DBO, TSO, or RP**	Order # or Plan #	Board Vote (Yes-No- Recuse)	Recused Board Members
53	H.E.B. Pharmacy #647	P	ABO	2020-04592	6-0-3	Lewis, Montemayor, Tijerina
54	Genee Bailey Schexnayder	R	ABO	2021-02510	6-0-3	Lewis, Montemayor, Tijerina
55	Jared Moses Hullaby	I	ABO	2021-01063	7-0-2	Lewis, Tisch
56	Reginald Winston McCoy	R	ABO	2021-02879	7-0-2	Lewis, Tijerina
57	Olaoluwa Oladejo	R	ABO	2021-02270	7-0-2	Lewis, Tijerina
58	US Compounding	P	ABO	2020-04981	7-0-2	Lewis, Tisch
59	Bartholomew A. Akubukwe	R	DBO	2021-00499	7-0-2	Lewis, Tijerina
60	<i>Confidential</i>	R	ABO	2021-03218	9-0-0	-
61	<i>Confidential</i>	R	ABO	2021-03125	7-0-2	Lewis, Tijerina
62	<i>Confidential</i>	I	ABO	2021-02719	7-0-2	Lewis, Tijerina
63	<i>Confidential</i>	I	ABO	2021-02784	7-0-2	Lewis, Tisch
64	<i>Confidential</i>	R	ABO	2021-01841	8-0-1	Henke
65	<i>Confidential</i>	R	ABO	2021-04718	7-0-2	Lewis, Tisch
66	<i>Confidential</i>	R	ABO	2021-00257	7-0-2	Lewis, Tijerina
67	<i>Confidential</i>	R	ABO	2021-00739	8-0-1	Henke
68	<i>Confidential</i>	R	ABO	2021-03056	7-0-2	Lewis, Tijerina
69	<i>Confidential</i>	R	ABO	2021-01968	7-0-2	Lewis, Tisch
70	Ngoc-Diem Do	R	RP	2021-01661	9-0-0	-
71	Shirley Hong	R	RP	2021-01660	9-0-0	-
72	Pascal Nnamdi Ike	R	RP	2021-01967	9-0-0	-
73	Robert H. Mayes	R	RP	2021-02486	9-0-0	-
74	Alison McCullough	R	RP	2021-01673	9-0-0	-
75	Marsha D. Nichols	R	RP	2021-04027	9-0-0	-
76	Thu Quynh Pham	R	RP	2021-01214	9-0-0	-
77	Byron Scott Singleton	R	RP	2021-01667	9-0-0	-
78	Kanwal Fatima Abbas	R	RP	2020-04799	7-0-2	Lewis, Tijerina
79	Power Center Pharmacy #2	P	RP	2021-02633	7-0-2	Lewis, Tijerina
80	Ann Nguyen	R	RP	2021-02901	7-0-2	Lewis, Tijerina

*Technician or Technician Trainee (T), Intern (I), Pharmacist (R), and Pharmacy (P)

**Agreed Board Order (ABO), Default Board Order (DBO), Temporary Suspension Order (TSO), and Remedial Plan (RP)

I. Election of Board Officers

President Spier called for nominations for the offices of Vice President and Treasurer. Ms. Yoakum motioned to nominate Ms. Henke as Vice President. The motion was seconded by Mr. Lewis. A roll-call vote was taken, and the motion passed with Ms. Henke abstained. Ms. Montemayor motioned to nominate Mr. Fernandez as Treasurer. The motion was seconded by Mr. Guerrero and passed unanimously.

J. Miscellaneous


- Items to be Placed on Agenda for November 2, 2021 Board Meeting:
 - Review of Board Mission Statement
- Discussion of and Possible Action on Upcoming Meetings

President Spier reminded Board Members about upcoming informal conferences.

Ms. Henke made a motion to adjourn the meeting. The motion was seconded by Mr. Lewis.

President Spier adjourned the meeting at 1:29 p.m.

APPROVED:



Julie Spier, R.Ph.
President



Timothy L. Tucker, Pharm.D.
Executive Director/Secretary

November 2, 2021